Myeloid and lymphoid neoplasms with abnormalities of the fibroblast growth factor receptor 1 gene (FGFR1) have been recognized as a distinct disease group by the 2008 World Health Organization classification of hematopoietic neoplasms. 1 This neoplasm was initially described by Macdonald and colleagues 2 as a myeloproliferative neoplasm with eosinophilia, lymphadenopathy, and a high incidence of T-cell non-Hodgkin lymphoma with progression to acute myeloid leukemia. The term 8p11 myeloproliferative syndrome (EMS) was coined to describe this distinct entity. This is a rare and aggressive hematopoietic neoplasm associated with rearrangement of FGFR1 on chromosome 8p11 to at least 14 currently identified partner genes, with ZMYM2 (ZNF198) on chromosome 13q12 being the most common partner gene. 3, 4 The resultant fusion gene encodes an aberrant tyrosine kinase that is likely responsible for the pathogenesis of this disease. This neoplasm occurs over a wide age range of 3 to 84 years, with a median of 44 years, and with a very slight male predominance (male to female ratio of 1.2:1). 4 Many cases present as a myeloproliferative neoplasm with eosinophilia in the marrow, most of which also present with a T-lymphoblastic lymphoma (T-LL) or acute myeloid leukemia. Few cases presenting with B-lymphoblastic lymphoma have been reported. We report a rare case of a myeloid and lymphoid neoplasm with abnormalities of FGFR1 harboring a dual translocation of t(8;13)(p11.2;q12) and t(17;21)(p13;q22) involving runt-related transcription factor 1 gene (RUNX1) and presenting as a myeloproliferative neoplasm with immunophenotypically aberrant myeloid, B-lymphoid, and T-lymphoid blasts in the marrow and concurrent T-LL in the cervical node. A review of the current literature summarizing
Case Report
The patient was a 29-year-old African American man who initially sought treatment from an outside institution for fever and cervical lymphadenopathy. CBC at initial presentation (per report) was as follows: hemoglobin, 157 g/L; WBCs, 49.3 × 10 9 /L; platelets, 114 × 10 9 /L; and a differential of 37% neutrophils and precursors, 10% lymphocytes, 14% monocytes, 7% eosinophils, and 1% basophils. Fineneedle aspiration of the cervical lymph node showed a T-LL by morphology and flow cytometry. Bone marrow biopsy specimen was remarkable for myeloid expansion with eosinophilia by morphology. Cytogenetic and fluorescent in situ hybridization (FISH) studies showed 47,XY,t(8;13), +21 [20] per report. Based on the diagnostic bone marrow findings and concurrent T-LL involving the cervical lymph nodes, a diagnosis of myeloid and lymphoid neoplasm with abnormalities of FGFR1 was rendered. The patient was started on hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) chemotherapy with central venous system prophylaxis. A day 28 marrow report indicated a persistent FGFR1 rearrangement in a hypercellular marrow with granulocytosis and dysmegakaryopoiesis, as well as many atypical spindle-shaped mast cells in focal aggregates. Sequencing studies were negative for KIT mutations in the marrow. The patient completed the hyper-CVAD regimen with omission of doxorubicin due to worsening cardiac function.
Two months following the cessation of chemotherapy at the outside hospital, the patient came to our institution with cervical lymphadenopathy and fever. CBC was as follows: WBCs, 59 × 10 9 /L; RBCs, 4.2 × 10 9 /L; hemoglobin, 10.7 g/ dL; hematocrit, 33.6%; mean corpuscular volume, 80.2 fL; red cell distribution width, 22.3%; and platelets 56 × 10 9 /L. The peripheral blood smear showed normocytic normochromic anemia, thrombocytopenia, and marked leukocytosis with absolute neutrophilia and left-shifted granulocytes (47%) with occasional circulating blasts (2%), eosinophilia (21%), and monocytosis (23%). The eosinophils displayed atypical morphologic features, including cytoplasmic vacuolization, enlarged size, and hyposegmentation. The marrow was hypercellular with left-shifted granulocytic expansion (36%), eosinophilia (42%), mild basophilia (2%), and mildly increased blasts (5%) that were composed of 3% CD34+ and CD117+ myeloid blasts, as well as 2% B-lymphoblasts that were positive for PAX-5, CD10, Tdt, and CD20 ❚Image 1❚ by immunohistochemistry. Mast cells were increased in number in a diffuse interstitial pattern with spindle cell morphology and were positive for CD117, weakly positive for CD25, and negative for CD2. Four-color flow cytometry was performed 5 and revealed the presence of three distinct populations of immunophenotypically aberrant blasts, including B-lymphoblasts (0.26%), T-lymphoblasts (0.04%), and myeloblasts (2.6%) ❚Image 2❚. The bone marrow was cultured for 24 hours in RPMI 1640 and then harvested. Chromosome analysis was performed following standard protocols. International System for Human Cytogenetic Nomenclature 2013 was followed to described the G-banded karyotype. 6 Conventional karyotype analysis and FISH studies showed 46,XY,t(8;13)(p11.2;q12),t(17;21)(p13;q22) in all 20 cells analyzed ❚Image 3A❚ and ❚Image 3B❚. Additional FISH studies confirmed RUNX1 rearrangement ❚Image 3C❚. Immunophenotypic analysis performed on the fine-needle aspirate from the cervical lymph node revealed a 58% population of blasts with myeloid and T-lymphoid features that could not be comprehensively characterized due to specimen paucicellularity ❚Image 4❚. Morphologic assessment supported these findings (not shown). The apparent immunophenotypic variation between the T-lymphoblast populations in the lymph node and bone marrow is likely attributable to the fact that the two populations are vastly different in relative size. In addition, the lymph node specimen was limited by paucicellularity and could not be comprehensively characterized. The patient was initiated on a mitoxantrone, etoposide, and cytarabine chemotherapy regimen with a plan for an autologous bone marrow transplant. Unfortunately, the patient died of complications of disease 1 month later.
Discussion
Myeloid and lymphoid neoplasms with abnormalities of FGFR1, also known as EMS, are rare and aggressive hematopoietic neoplasms with a high mortality rate, as evidenced in our patient who died of disease 10 months after initial diagnosis. The incidence of transformation to acute myeloid leukemia, lymphoblastic leukemia, or rarely myeloid sarcoma is very high, and very few patients remain in the chronic phase for prolonged periods of time. 4 To our knowledge, 93 cases of myeloid and lymphoid neoplasms with abnormalities of FGFR1 have been reported in the literature ❚Table 1❚. 4, FGFR1 belongs to a family of four high-affinity receptor tyrosine kinases (FGFR1-4) that are vital to embryonic growth, development, and differentiation, including bone formation. 79 FGFR signaling is crucial for normal osteoblastogenesis and chondroblastogenesis, and mutations in this family of genes have been implicated in many skeletal anomalies. FGFR1 pharmacologic inhibitors have been shown to prevent skeletal abnormalities in mice models. FGFR signaling has also been implicated in many cancers, including uterine, cervical, prostate, bladder, colorectal, lung, and pilocytic astrocytoma, to name a few. 80 intermediary factor 1a) at 7q34, MYO 18A (myosin XVIII A) at 17q23, CPSF6 (cleavage and polyadenylation specificity factor) at 12q15, LRRFIP1 (leucine-rich repeat flightless interacting protein 1) at 2q37, RANBP2/NUP358 (nucleoporin of 358 kDa) at 2q12, TPR (translocated promoter region) at 1q25, NUP98 (nucleoporin of 98 kDa) at 11p15, HERVK (human endogenous retrovirus K) at 19q13.3, and CUX1 (cutlike homeobox 1) at 7q11 ( Table 1) .
The most frequent translocation is t(8;13)(p11;q12), seen in 40% of the reported cases, followed by t(8;22), t(8;9), and t(6;8), each representing 18%, 15%, and 9% cases, respectively (Table 1) . These translocations with the 8p11 breakpoint yield different fusion genes, all encoding aberrant tyrosine kinases. In vitro studies show good efficacy of various tyrosine kinase inhibitors (TKIs) such as PKC412, TKI258, and ponatinib in FGFR1 rearranged cell lines, with some promising clinical responses with TKI258 and PKC412, and also interferon a. 68, [81] [82] [83] [84] However, a single TKI has not been successfully established clinically thus far for this disease entity. It is highly possible that the stem cells and/or neoplastic progenitors acquire additional genetic alterations, including mutations to escape targeted inhibition of the aberrantly encoded tyrosine kinase. Moreover, this neoplasm is highly resistant to conventional chemotherapy, and allogeneic stem cell transplantation remains the only hope for remission but with dismal results. Our patient harbored t(8;13)(p11;q12) that results in an aberrant tyrosine kinase from the fusion of the dimerization and zinc finger domains of ZNF198 with the cytoplasmic tyrosine kinase domain of FGFR1. ZNF198 is a transcription factor with zinc finger, dimerization, and nuclear localization domains. 85 The fusion protein relocalizes to the cytoplasm from the cell membrane, with activation of downstream signaling pathways and transcription factors that are important for carcinogenesis. 86 Interesting and unique features in our case were the presence of three distinct populations of immunophenotypically aberrant blasts, including those of B, T, and myeloid lineage in a background of myeloproliferation, including eosinophilia. The recently revised model of hematopoiesis postulates that stem cells diverge into the myeloid-erythroid progenitor and the common myeloid-lymphoid progenitor. 87 This case supports this model by illustrating that the FGFR1 rearranged neoplasm is postulated to arise from a pluripotent stem cell possessing the potential of multilineage differentiation into B, T, or myeloid lineages. Findings similar to our patient have been reported in a patient harboring t(8;22) and having T-LL in the cervical nodes and a leukemia comprising predominantly myeloperoxidase-positive myeloid blasts, with a 20% subpopulation also expressing CD10 and CD19. 45 The findings in this patient are more consistent with a mixed-phenotype acute leukemia and T-LL in the cervical nodes.
A novel molecular finding in our case is the presence of an additional t(17;21)(p13;q22) in the marrow. FISH studies with probes specific for RUNX1 confirmed a rearrangement in this gene. The t(17;21)(p13;q22) is not a specific recurrent C B A ❚Image 3❚ Cytogenetic and fluorescent in situ hybridization (FISH) findings. A, Conventional cytogenetics showed an abnormal karyotype with two translocations involving the short arms of chromosomes 8 and 13 and the short arms of chromosomes 17 and 21. 46,XY,t(8;13)(p11.2;q12),t(17;21)(p13;q22). B, Interphase FISH analysis with FGFR1 break-apart and CEP-8 probe combination. Note one normal copy of FGFR1 (red/green fusion signal) and rearranged copy of FGFR1 with only green and missing red (3′-centromeric portion). C, Metaphase FISH showing intact FGFR1 on normal 8, no signal on der(8)t(8;13) chromosome (this had only CEP-8 signal) and green signal on der(13) chromosome.
cytogenetic abnormality, and no report of this rearrangement has been found in current literature. In all probability, a region of chromosome 17 has translocated to the RUNX1 locus, resulting in disruption of this gene. RUNX1 encodes the a subunit of the heterodimeric transcription factor, core binding factor (CBF). RUNX1 binds to DNA and interacts with its heterodimerization partner, CBFb, the target of the inv(16)(p13q22)/t(16;16)(p13;q22), and these actions are mediated through the runt domain. 88 Heterodimerization of RUNX1 and CBFb increases the DNA-binding affinity of RUNX1. RUNX1 is crucial for normal hematopoietic precursor development in the marrow, and this has been illustrated in mice models that lack this gene and show complete absence of hematopoiesis and early embryonic death in utero. 89 Conditional knockout of RUNX1 in adult mice results in significant expansion of the hematopoietic stem cells and myeloid progenitors, thrombocytopenia, lymphopenia, and myeloproliferation in the spleen and thymus. 90 In addition, rearrangements in RUNX1 are the most common genetic abnormality in myeloid neoplasms, and at least 12 different partner genes have been described, the most common being ETO, MTG8, and RUNX1T1. While the mechanism by which potential cooperative oncogenesis conferred by FGFR1 and RUNX1 rearrangements in our patient is unknown, the presence of RUNX1 rearrangement may suggest that the clonal instability in the stem cell that harbors the FGFR1 rearrangement results in acquisition of additional molecular abnormalities.
From the review of case reports (Table 1) , 4, it appears that a small subset of cases of t(8;13)(p11;q12); FGFR1-ZNF198 showed additional, often simple chromosomal aberrancies, including +21. This is in contrast to cases of t(8;22)(p11.2;q11.2). FGFR1-BCR rearrangement cases frequently have additional complex chromosomal aberrancies. Many cases of t(8;13)(p11;q12) without additional chromosomal aberrancies have also shown features of multilineage differentiation. This may suggest that disruptions caused by FGFR1-ZNF198 rearrangement occur in stem cells or more primitive progenitors and result in more powerful oncogenetic events, which is capable of inducing multilineage differentiation and contributing to the dismal clinical course of this neoplasm.
Our case also illustrates the importance of flow cytometric analysis to comprehensively analyze the immunophenotype of blasts and assess for multiple lineage differentiation. Notably, the percentage of three blast populations was low in this case, which may not be detectable by routine morphologic examination. Flow cytometric analysis is more suitable in this setting to accurately characterize the disease features. BCR t(6;11)(q11;p13), del(9)(p13p22), inv(2)(p11.2q31), t(3;7) (q23;q11.2), add(7)(p13), der(9)t(7;9)(p15;p22), inv(17) (p11.2q21), and an extra copy of der (8) AML, acute myeloid lymphoma; AMML, acute myelomonocytic leukemia; B-LL, B-lymphoblastic lymphoma; BMT, bone marrow transplant; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; Ph, Philadelphia chromosome; PV, polycythemia vera; RAEB, refractory anemia with excess blasts; T-LL, T-lymphoblastic lymphoma; T-NHL, T-cell non-Hodgkin lymphoma.
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In conclusion, our case portrays both classical and unique features of the myeloid and lymphoid neoplasms with eosinophilia and abnormalities of FGFR1 (t(8;13) (p11.2;q12);ZNF198-FGFR1) and reinforces that this is a highly aggressive disease with a dismal prognosis. We also report the novel finding of t(17;21)(p13;q22) with RUNX1 rearrangement as a potential cooperative oncogenetic event, which may partly contribute to the aggressive nature of this disease. Further research on signaling pathways conferred by these genetic alterations is necessary for individualized targeted therapy in the treatment of this aggressive hematopoietic neoplasm.
